Trop-2 Directed Antibody-Drug Conjugates for the Treatment of Solid Tumors

In this expert interview, Jacob Sands, MD, shares key insights on unmet needs in the treatment of lung cancer, comments on the role of clinical trials investigating Trop-2-targeted therapy, and considers the potential impact of datopotamab deruxtecan (Dato-DXd) on the treatment landscape if it receives FDA approval for use in lung cancer.

This article surveils key advancements in the role of antibody-drug conjugates in solid tumors by examining important clinical trial findings on targeting Trop-2 in breast and lung cancers.

This article provides an overview of antibody-drug conjugates for the treatment of solid tumors and examines emerging evidence demonstrating Trop-2 as a potential target in breast and lung cancers.